Co-Authors
This is a "connection" page, showing publications co-authored by CHRISTOPHER J LOGOTHETIS and MIAO ZHANG.
Connection Strength
0.788
-
A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2024 Jul 01; 30(13):2751-2763.
Score: 0.243
-
A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Na?ve Metastatic Prostate Cancer. Clin Cancer Res. 2020 03 01; 26(5):990-999.
Score: 0.179
-
Prostate cancer-induced endothelial-cell-to-osteoblast transition drives immunosuppression in the bone-tumor microenvironment through Wnt pathway-induced M2 macrophage polarization. Proc Natl Acad Sci U S A. 2024 Aug 13; 121(33):e2402903121.
Score: 0.061
-
A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates. BJU Int. 2024 Sep; 134(3):449-458.
Score: 0.061
-
Characterization of prostate cancer adrenal metastases: dependence upon androgen receptor signaling and steroid hormones. Prostate Cancer Prostatic Dis. 2023 Dec; 26(4):751-758.
Score: 0.054
-
MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nat Commun. 2022 04 04; 13(1):1797.
Score: 0.052
-
Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. Eur Urol Oncol. 2023 04; 6(2):228-232.
Score: 0.051
-
Assessment of Luminal and Basal Phenotypes in Bladder Cancer. Sci Rep. 2020 06 16; 10(1):9743.
Score: 0.046
-
Oncogenic and osteolytic functions of histone demethylase NO66 in castration-resistant prostate cancer. Oncogene. 2019 06; 38(25):5038-5049.
Score: 0.042